Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 4, Issue 7, Pages 481-483
IDB: New Salicylates

Topical Treatment of Ulcerative Colitis using Enemas Containing 5-Aminosalicylic Acid and Beclomethasone Dipropionate

M Campieri, P Gionchetti, A Belluzzi, M Tampieri, C Brignola, M Ferretti, M Miglioli, and L Barbara

lstituto di Clinica Medica e Gastroencerologia, Universita di Bologna, Bologna, Italy

Copyright © 1990 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


5-Aminosalicylic acid (5-ASA) enemas constitute a first-line therapy for patients with mild to moderate attacks of ulcerative colitis. To date, based on the results of different studies, 5-ASA enemas appear to be satisfactory in at least two-thirds of patients treated. Beclomethasone is one of the new corticosteroids which appear to have minimal systemic effects. The authors have assessed the efficacy of a four week course of 3 mg beclomethasone enemas compared to 2 g 5-ASA enemas in patients with ulcerative colitis. Preliminary analysis would suggest that both therapies are effective in more than 50% of cases.